Alfredo Acevedo Ramos, Clinical Oncologist at Serena del Mar Hospital, shared a post on LinkedIn:
“I’m very pleased to share our scientific publication, now available in Cancers, MDPI
As ADCs gain ground in neoadjuvant settings, are anthracyclines still an option in HER2-positive early breast cancer patients?
In our retrospective study, outcomes were comparable between anthracycline and anthracycline-free regimens.
There was a trend toward greater benefit in HR-positive and node-positive (N+) patients.
This supports safer alternatives for most, while highlighting subgroups that may still need more intensive therapy.”
Title: Oncologic Outcomes and Safety of Neoadjuvant Treatment with Anthracyclines Versus Anthracycline-Free Regimens in HER2-Positive Early Breast Cancer in a Colombian Cancer Center: An Observational, Analytical, Retrospective Study
Authors: Alfredo Acevedo-Ramos, Andrea Zuluaga-Liberato, and Sandra E. Díaz-Casas
You can read the Full Article in Cancers.
More posts on Breast Cancer on OncoDaily.